{"name":"Yooyoung Pharmaceutical Co., Ltd.","slug":"yooyoung-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"YYC506","genericName":"YYC506","slug":"yyc506","indication":"Type 2 diabetes","status":"phase_3"},{"name":"YYC405-T","genericName":"YYC405-T","slug":"yyc405-t","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Active comparator: Synovian Inj.","genericName":"Active comparator: Synovian Inj.","slug":"active-comparator-synovian-inj","indication":"Osteoarthritis of the knee","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Simdax","genericName":"Simdax","slug":"simdax","indication":"Congestive heart failure","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"YYC301-1 & YYC301-2 & YYC301-3","genericName":"YYC301-1 & YYC301-2 & YYC301-3","slug":"yyc301-1-yyc301-2-yyc301-3","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Active comparator: Synovian Inj.","genericName":"Active comparator: Synovian Inj.","slug":"active-comparator-synovian-inj","phase":"phase_3","mechanism":"Synovian is a hyaluronic acid-based intra-articular injection that lubricates and cushions the joint to reduce pain and improve mobility in osteoarthritis.","indications":["Osteoarthritis of the knee"],"catalyst":""},{"name":"YYC506","genericName":"YYC506","slug":"yyc506","phase":"phase_3","mechanism":"YYC506 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Simdax","genericName":"Simdax","slug":"simdax","phase":"phase_3","mechanism":"ATP-sensitive inward rectifier potassium channel 8, ATP-sensitive inward rectifier potassium channel 11, Troponin C, slow skeletal and cardiac muscles","indications":["Congestive heart failure"],"catalyst":""},{"name":"YYC301-1 & YYC301-2 & YYC301-3","genericName":"YYC301-1 & YYC301-2 & YYC301-3","slug":"yyc301-1-yyc301-2-yyc301-3","phase":"phase_3","mechanism":"YYC301-1, YYC301-2, and YYC301-3 are investigational drugs with unknown mechanisms of action.","indications":[],"catalyst":""},{"name":"YYC405-T","genericName":"YYC405-T","slug":"yyc405-t","phase":"phase_3","mechanism":"YYC405-T is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOLVlJc3JXdTZCR3pKMHhLclJMV0NhYksyQzJjZm5vOENGSUFQRzFIdHBvdzFvYXB3a3pSWGQ3RWtHZEpHMEJJcHZJXy1HdnNsejQ3TzV0bmZoenBMeFBCbjZwWERaekl3ZVJ4amcxNDlkZzJlM2V4VXgwLVdKSnhXYzFMSUVtcUkzNHlTei1IM254eF9TeHBQZzJR?oc=5","date":"2026-04-06","type":"trial","source":"openPR.com","summary":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com","headline":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxOTEhVS245emJONG1sZVR5RUIxQjR1NWdGVWY0SnBFNklIYmF4RDAtT3c4TlFBbElCTGhQSHVfUE1nX2FKLVF2Szc1U0VSYlphOVU2M21GTG4xYldtUmFkUEZuWlZfZ0NFNk4wazRPWngtTTZVajEyZjFJdGI2b3BOY2pBamhsSzZOR29aRlljamhVdkdZeHBNcGZyME0zLVYxUnYzT0FhdW5EbmhlR214bnVYVG1aTGNjZ0RzYWVjYXZJazgwTFFkamdJRGZvbm5BSWp6RU1yQWk2NG5VdGgtYWh0eVJkdjktUllTV1dmSVdfZ25oY2pMTkstREUybWdZZGFWTE9FWHdaelZBOXBZ?oc=5","date":"2025-09-16","type":"pipeline","source":"Business Wire","summary":"Celltrion Pharm Signs Strategic Trilateral Agreement with Becton Dickinson and BD Korea to Accelerate Global PFS CMO Business - Business Wire","headline":"Celltrion Pharm Signs Strategic Trilateral Agreement with Becton Dickinson and BD Korea to Accelerate Global PFS CMO Bus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxPejRGZWJpTmZNNWVJdm9YTHBrVk5xakRVV1NsbVhjQUxiVm9rbTc5OXBkMUpfVmRGMW9MOFpCcUliakR0emU4UjBrWUNIZWZQRlhoVEU1ODhHUWcxOGdkY3hIektmaGRoVDJMX1hTSllXTnBjbi1qYlE3cHY5QTN1SW1VcHpnc1NJbDdpcElkZW5JbmNiZ24taE5sVWRWZ0VIVkNYOHdvSTZXYVpKOXZDSFpNLVFlOEZJaFFxQkFLckM4WlA1aTJwT01XcW4xREsya0JYT1JJcHRHYmJwMExJNzRmeEYzZU1kTVNNdm5kVUlzN2xvcEJpWG8wNnBoU000N2Z4N2FvSU5pY29zeVFHNkVMbUU3RzhSbFh0a0hQNVE0eVFOQk4wdjBZYlg?oc=5","date":"2024-08-15","type":"pipeline","source":"GlobeNewswire","summary":"Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire","headline":"Global Non-Steroidal Anti-Inflammatory Drugs Market is","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9YSk50SjMyVGpBQ3JFZDFaSmlWZ2dxend4NXhtUGdkem9HeHNma0RVdTRGX3YtWW9aVExiYXdOTXZqS0VpTnNtUGVHR0h2bXJ2TDF3ZEZHakdlYm5SblZoSmhDSDRiaTZNaFg2ZFZR0gFyQVVfeXFMUEdHUlg3Q2xmVDhhckRFWW5Rcm9vY0w3MVJVTHZNOE9acjFaOVBUQ3pFdGVXM0Iwd2pLbUpPWVFCRjUzc0ZUN2Q2TnVuR0RhLTI4Z3JwaHNrVGJUNXl6YWdyZHQwbWxWb3I5VFlfMzBmWEhR?oc=5","date":"2024-05-16","type":"pipeline","source":"koreabiomed.com","summary":"Regulator orders Kukje Pharma to recall fluoxetine hydrochloride products - koreabiomed.com","headline":"Regulator orders Kukje Pharma to recall fluoxetine hydrochloride products","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPNU8tcmxoYUg1NTZqOElUbHliUUxDY0pHNlA1bnI0ajhJVXc1QUowQU1BVGxJeC1SX2FobXJpemlpaGJIc19YOTlaSV9hYTVJSWN2bTJHUENhZ3Q5aEUzNlVLTDBfOHl0ejlNT2hyT082c0JIWWxyc184VzZ3ZmxDQU5zdE5tNkQ0Zkh1dnFnREhySVFPV3JXb1NhdU42aVl3bC1hSE9ibw?oc=5","date":"2024-05-13","type":"pipeline","source":"BioWorld News","summary":"Bio Korea 2024: Curocell CEO points to rise, fall of CAR T trends - BioWorld News","headline":"Bio Korea 2024: Curocell CEO points to rise, fall of CAR T trends","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":5},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}